Positive feedback between oncogenic KRAS and HIF-1α confers drug resistance in colorectal cancer

References

• SiegelRDesantisCJemalAColorectal cancer statistics, 2014CA Cancer J Clin201464210411724639052
   PubMed Web of Science ®Google Scholar
• HawleySTChangSRisserDZhangQColorectal cancer incidence and mortality in Texas 1990–1992: a comparison of rural classificationsJ Rural Health200218453654612380896
   PubMed Web of Science ®Google Scholar
• WheelerDLDunnEFHarariPMUnderstanding resistance to EGFR inhibitors-impact on future treatment strategiesNat Rev Clin Oncol20107949350720551942
   PubMed Web of Science ®Google Scholar
• MasekiSIjichiKNakanishiHHasegawaYOgawaTMurakamiSEfficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinomaMol Clin Oncol20131591892424649271
   PubMedGoogle Scholar
• FenstererHSchade-BrittingerCMüllerHHMulticenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)Ann Oncol201324102576258123897705
   PubMed Web of Science ®Google Scholar
• KullmannFHartmannAStöhrRKRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapyOncology20118113821894049
   PubMed Web of Science ®Google Scholar
• LièvreABachetJBLe CorreDKRAS mutation status is predictive of response to cetuximab therapy in colorectal cancerCancer Res20066683992399516618717
   PubMed Web of Science ®Google Scholar
• SiddiquiADPiperdiBKRAS mutation in colon cancer: a marker of resistance to EGFR-I therapyAnn Surg Oncol20101741168117619936839
   PubMed Web of Science ®Google Scholar
• MonzonFAOginoSHammondMEHallingKCBloomKJNikiforovaMNThe role of KRAS mutation testing in the management of patients with metastatic colorectal cancerArch Pathol Lab Med2009133101600160619792050
   PubMed Web of Science ®Google Scholar
• TanCDuXKRAS mutation testing in metastatic colorectal cancerWorld J Gastroenterol201218375171518023066310
   PubMed Web of Science ®Google Scholar
• CéspedesMVSanchoFJGuerreroSK-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12Carcinogenesis200627112190220016679305
   PubMed Web of Science ®Google Scholar
• KumarSSPriceTJMohyieldinOBorgMTownsendAHardinghamJEKRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line ModelGastrointest Cancer Res201471232624558511
   PubMedGoogle Scholar
• IhleNTByersLAKimESEffect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomeJ Natl Cancer Inst2012104322823922247021
   PubMed Web of Science ®Google Scholar
• BergMSoreideKEGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapyDiscov Med2012147620721423021375
   PubMed Web of Science ®Google Scholar
• WeeSJaganiZXiangKXPI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancersCancer Res200969104286429319401449
   PubMed Web of Science ®Google Scholar
• BrownJMTumor hypoxia, drug resistance, and metastasesJ Natl Cancer Inst19908253383392406450
   PubMedGoogle Scholar
• MinardFNGrantDSHypothermia as a mechanism for drug-induced resistance to hypoxiaBiochem Pharmacol1982317119712037092915
   PubMed Web of Science ®Google Scholar
• SakataKKwokTTMurphyBJLaderouteKRGordonGRSutherlandRMHypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistanceBr J Cancer19916458098141681885
   PubMed Web of Science ®Google Scholar
• SantoniMPantanoFAmantiniCEmerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinomaBiochim Biophys Acta20141845222123124480319
   PubMed Web of Science ®Google Scholar
• TanimotoKMakinoYPereiraTPoellingerLMechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor proteinEMBO J200019164298430910944113
   PubMed Web of Science ®Google Scholar
• LiuXJakubowskiMHuntJLKRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosisAm J Clin Pathol2011135224525221228365
   PubMed Web of Science ®Google Scholar
• ShaibWMahajanREl-RayesBMarkers of resistance to anti-EGFR therapy in colorectal cancerJ Gastrointest Oncol20134330831823997942
   PubMedGoogle Scholar
• RuzzoAGrazianoFCanestrariEMagnaniMMolecular predictors of efficacy to anti-EGFR agents in colorectal cancer patientsCurr Cancer Drug Targets2010101687920088793
   PubMed Web of Science ®Google Scholar
• JacobyJJErezBKorshunovaMVTreatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in miceJ Thorac Oncol20105794094920512076
   PubMed Web of Science ®Google Scholar
• PalayoorSTMitchellJBCernaDDegraffWJohn-AryankalayilMColemanCNPX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cellsInt J Cancer2008123102430243718729192
   PubMed Web of Science ®Google Scholar
• OstremJMPetersUSosMLWellsJAShokatKMK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsNature2013503747754855124256730
   PubMed Web of Science ®Google Scholar
• SienaSSartore-BianchiADi NicolantonioFBalfourJBardelliABiomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancerJ Natl Cancer Inst20097101191308132419738166
   PubMedGoogle Scholar
• ZengMKikuchiHPinoMSChungDCHypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cellsPLoS One201056e1096620532039
   PubMed Web of Science ®Google Scholar
• MillsCNJoshiSSNilesRMExpression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditionsMol Cancer2009810419919690
   PubMed Web of Science ®Google Scholar
• KohMYSpivak-KroizmanTVenturiniSMolecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alphaMol Cancer Ther2008719010018202012
   PubMed Web of Science ®Google Scholar
• LeeKKimHMA novel approach to cancer therapy using PX-478 as a HIF-1α inhibitorArch Pharm Res201134101583158522076756
   PubMed Web of Science ®Google Scholar
• JacobyJJErezBTakahashiOAbstract 3632: Addition of the HIF-1α inhibitor PX-478 enhances the therapeutic efficacy of EGFR inhibitors in an orthotopic human lung adenocarcinoma modelCancer Res2010703632
   Google Scholar
• MaJMengYKwiatkowskiDJMammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascadeJ Clin Invest2010120110311420038814
   PubMed Web of Science ®Google Scholar